{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:33:26Z","timestamp":1783449206304,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI139473"],"award-info":[{"award-number":["AI139473"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-21238-5","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:57:23Z","timestamp":1761296243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Flagellin co-expression potentiates mRNA vaccine-induced cytotoxic T lymphocyte responses but not anti-tumor immunity"],"prefix":"10.1038","volume":"15","author":[{"given":"Yibo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinliang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Labone","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"VanLuinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayachandra Reddy","family":"Nakkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"21238_CR1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150. https:\/\/doi.org\/10.1038\/s41586-023-06063-y (2023).","journal-title":"Nature"},{"key":"21238_CR2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet (London England). 403, 632\u2013644. https:\/\/doi.org\/10.1016\/S0140-6736(23)02268-7 (2024).","journal-title":"Lancet (London England)"},{"key":"21238_CR3","doi-asserted-by":"publisher","unstructured":"Karimi-Sani, I. et al. Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials. J. Nanobiotechnol. 22 https:\/\/doi.org\/10.1186\/s12951-024-02882-x (2024).","DOI":"10.1186\/s12951-024-02882-x"},{"key":"21238_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","volume":"621","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621, 396\u2013403. https:\/\/doi.org\/10.1038\/s41586-023-06127-z (2023).","journal-title":"Nature"},{"key":"21238_CR5","doi-asserted-by":"publisher","first-page":"eabg2200","DOI":"10.1126\/sciimmunol.abg2200","volume":"8","author":"H Xia","year":"2023","unstructured":"Xia, H. et al. Computational prediction of MHC anchor locations guides neoantigen identification and prioritization. Sci. Immunol. 8, eabg2200. https:\/\/doi.org\/10.1126\/sciimmunol.abg2200 (2023).","journal-title":"Sci. Immunol."},{"key":"21238_CR6","doi-asserted-by":"publisher","first-page":"eadn9961","DOI":"10.1126\/sciadv.adn9961","volume":"10","author":"T Fan","year":"2024","unstructured":"Fan, T. et al. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity. Sci. Adv. 10, eadn9961. https:\/\/doi.org\/10.1126\/sciadv.adn9961 (2024).","journal-title":"Sci. Adv."},{"key":"21238_CR7","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.ymthe.2021.03.002","volume":"29","author":"SW Tse","year":"2021","unstructured":"Tse, S. W. et al. mRNA-encoded, constitutively active STING(V155M) is a potent genetic adjuvant of antigen-specific CD8(+) T cell response. Mol. Therapy: J. Am. Soc. Gene Therapy. 29, 2227\u20132238. https:\/\/doi.org\/10.1016\/j.ymthe.2021.03.002 (2021).","journal-title":"Mol. Therapy: J. Am. Soc. Gene Therapy"},{"key":"21238_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao, T. et al. Vaccine adjuvants: mechanisms and platforms. Signal. Transduct. Target. Ther. 8, 283. https:\/\/doi.org\/10.1038\/s41392-023-01557-7 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"21238_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2017.06.005","volume":"47","author":"AS McKee","year":"2017","unstructured":"McKee, A. S. & Marrack, P. Old and new adjuvants. Curr. Opin. Immunol. 47, 44\u201351. https:\/\/doi.org\/10.1016\/j.coi.2017.06.005 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"21238_CR10","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Kariko","year":"2008","unstructured":"Kariko, K. et al. Incorporation of Pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Therapy: J. Am. Soc. Gene Therapy. 16, 1833\u20131840. https:\/\/doi.org\/10.1038\/mt.2008.200 (2008).","journal-title":"Mol. Therapy: J. Am. Soc. Gene Therapy"},{"key":"21238_CR11","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1038\/emm.2017.172","volume":"49","author":"IA Hajam","year":"2017","unstructured":"Hajam, I. A., Dar, P. A., Shahnawaz, I., Jaume, J. C. & Lee, J. H. Bacterial flagellin-a potent Immunomodulatory agent. Exp. Mol. Med. 49, e373. https:\/\/doi.org\/10.1038\/emm.2017.172 (2017).","journal-title":"Exp. Mol. Med."},{"key":"21238_CR12","doi-asserted-by":"publisher","unstructured":"Zheng, J. H. et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous Flagellin. Sci. Transl Med. 9 https:\/\/doi.org\/10.1126\/scitranslmed.aak9537 (2017).","DOI":"10.1126\/scitranslmed.aak9537"},{"key":"21238_CR13","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1016\/j.vaccine.2013.06.054","volume":"31","author":"CT Nguyen","year":"2013","unstructured":"Nguyen, C. T. et al. Flagellin enhances tumor-specific CD8(+) T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model. Vaccine 31, 3879\u20133887. https:\/\/doi.org\/10.1016\/j.vaccine.2013.06.054 (2013).","journal-title":"Vaccine"},{"key":"21238_CR14","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.2c01028","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y., Li, Z., Voyer, J., Li, Y. & Chen, X. Flagellin\/Virus-like particle hybrid platform with high Immunogenicity, Safety, and versatility for vaccine development. ACS Appl. Mater. Interfaces. https:\/\/doi.org\/10.1021\/acsami.2c01028 (2022).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"21238_CR15","doi-asserted-by":"publisher","first-page":"120030","DOI":"10.1016\/j.biomaterials.2020.120030","volume":"249","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y., Li, Z., Zhu, X., Cao, Y. & Chen, X. Improving immunogenicity and safety of Flagellin as vaccine carrier by high-density display on virus-like particle surface. Biomaterials 249, 120030. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120030 (2020).","journal-title":"Biomaterials"},{"key":"21238_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-1-4939-9167-9_8","volume":"1960","author":"YS Tan","year":"2019","unstructured":"Tan, Y. S. & Lei, Y. L. Isolation of Tumor-Infiltrating lymphocytes by Ficoll-Paque density gradient centrifugation. Methods Mol. Biol. 1960, 93\u201399. https:\/\/doi.org\/10.1007\/978-1-4939-9167-9_8 (2019).","journal-title":"Methods Mol. Biol."},{"key":"21238_CR17","doi-asserted-by":"publisher","first-page":"8268","DOI":"10.1016\/j.vaccine.2010.10.009","volume":"28","author":"JJ Treanor","year":"2010","unstructured":"Treanor, J. J. et al. Safety and immunogenicity of a Recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28, 8268\u20138274. https:\/\/doi.org\/10.1016\/j.vaccine.2010.10.009 (2010).","journal-title":"Vaccine"},{"key":"21238_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/cdd.2009.206","volume":"17","author":"SP Cullen","year":"2010","unstructured":"Cullen, S. P., Brunet, M. & Martin, S. J. Granzymes in cancer and immunity. Cell. Death Differ. 17, 616\u2013623. https:\/\/doi.org\/10.1038\/cdd.2009.206 (2010).","journal-title":"Cell. Death Differ."},{"key":"21238_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic, D., Song, M., Wang, L. & Zhang, Y. Roles of IFN-gamma in tumor progression and regression: a review. Biomark. Res. 8, 49. https:\/\/doi.org\/10.1186\/s40364-020-00228-x (2020).","journal-title":"Biomark. Res."},{"key":"21238_CR20","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1016\/j.vaccine.2011.05.041","volume":"29","author":"CB Turley","year":"2011","unstructured":"Turley, C. B. et al. Safety and immunogenicity of a Recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29, 5145\u20135152. https:\/\/doi.org\/10.1016\/j.vaccine.2011.05.041 (2011).","journal-title":"Vaccine"},{"key":"21238_CR21","doi-asserted-by":"publisher","unstructured":"Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol. Cancer. 22 https:\/\/doi.org\/10.1186\/s12943-023-01723-z (2023).","DOI":"10.1186\/s12943-023-01723-z"},{"key":"21238_CR22","doi-asserted-by":"publisher","first-page":"120844","DOI":"10.1016\/j.biomaterials.2021.120844","volume":"274","author":"KS Park","year":"2021","unstructured":"Park, K. S., Nam, J., Son, S. & Moon, J. J. Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8(+) T cells. Biomaterials 274, 120844. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.120844 (2021).","journal-title":"Biomaterials"},{"key":"21238_CR23","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1084\/jem.20080099","volume":"205","author":"SA Quezada","year":"2008","unstructured":"Quezada, S. A. et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205, 2125\u20132138. https:\/\/doi.org\/10.1084\/jem.20080099 (2008).","journal-title":"J. Exp. Med."},{"key":"21238_CR24","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/mt.2010.312","volume":"19","author":"J Li","year":"2011","unstructured":"Li, J. et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol. Therapy: J. Am. Soc. Gene Therapy. 19, 650\u2013657. https:\/\/doi.org\/10.1038\/mt.2010.312 (2011).","journal-title":"Mol. Therapy: J. Am. Soc. Gene Therapy"},{"key":"21238_CR25","doi-asserted-by":"publisher","first-page":"1074644","DOI":"10.3389\/fimmu.2022.1074644","volume":"13","author":"JT Gordy","year":"2022","unstructured":"Gordy, J. T. et al. IFNalpha and 5-Aza-2\u2019-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model. Front. Immunol. 13, 1074644. https:\/\/doi.org\/10.3389\/fimmu.2022.1074644 (2022).","journal-title":"Front. Immunol."},{"key":"21238_CR26","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1016\/j.vaccine.2019.05.018","volume":"37","author":"EJ Ko","year":"2019","unstructured":"Ko, E. J. et al. Flagellin-expressing virus-like particles exhibit adjuvant effects on promoting IgG isotype-switched long-lasting antibody induction and protection of influenza vaccines in CD4-deficient mice. Vaccine 37, 3426\u20133434. https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.018 (2019).","journal-title":"Vaccine"},{"key":"21238_CR27","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/eji.201041089","volume":"41","author":"S Bobat","year":"2011","unstructured":"Bobat, S. et al. Soluble flagellin, FliC, induces an Ag-specific Th2 response, yet promotes T-bet-regulated Th1 clearance of Salmonella typhimurium infection. Eur. J. Immunol. 41, 1606\u20131618. https:\/\/doi.org\/10.1002\/eji.201041089 (2011).","journal-title":"Eur. J. Immunol."},{"key":"21238_CR28","doi-asserted-by":"publisher","first-page":"212215","DOI":"10.4049\/jimmunol.194.Supp.212.5","volume":"194","author":"K Smith","year":"2015","unstructured":"Smith, K., Lopez-Yglesias, A., Lu, C., Zhao, X. & Strong, R. Flagellin\u2019s hypervariable D2\/D3 domain is required for robust anti-flagellin primary antibody responses (VAC11P.1065). J. Immunol. 194, 212215\u2013212215 (2015).","journal-title":"J. Immunol."},{"key":"21238_CR29","doi-asserted-by":"publisher","unstructured":"Nempont, C. et al. Deletion of flagellin\u2019s hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. Journal of immunology (Baltimore, Md.:) 181, 2036\u20132043, ) 181, 2036\u20132043, (1950). https:\/\/doi.org\/10.4049\/jimmunol.181.3.2036 (2008).","DOI":"10.4049\/jimmunol.181.3.2036"},{"key":"21238_CR30","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.4161\/hv.23809","volume":"9","author":"J Yang","year":"2013","unstructured":"Yang, J. et al. Antigen replacement of domains D2 and D3 in Flagellin promotes mucosal IgA production and attenuates Flagellin-induced inflammatory response after intranasal immunization. Hum. Vaccines Immunotherapeutics. 9, 1084\u20131092. https:\/\/doi.org\/10.4161\/hv.23809 (2013).","journal-title":"Hum. Vaccines Immunotherapeutics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21238-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21238-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21238-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:57:23Z","timestamp":1761296243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21238-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21238"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-21238-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37280"}}